Related Experiment Video
Updated: Apr 15, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
BEVACIZUMAB LEVELS IN BREAST MILK AFTER LONG-TERM INTRAVITREAL INJECTIONS
Trevor J McFarland1, Andrew D Rhoads, Matthew Hartzell
1*Casey Eye Institute, Oregon Health and Science University, Portland, Oregon; †Cullen Eye Institute, Baylor College of Medicine; and ‡Retina Center of Minnesota, Minneapolis, Minnesota.
Purpose:
The purpose of this study is to determine whether bevacizumab is detectable in the breast milk of nursing mothers.
Methods:
Breast milk samples were collected from 2 patients receiving monthly intravitreal bevacizumab injections for choroidal neovascularization over the course of 16 months. Enzyme-linked immunosorbent assay and Western blot analysis was used to determine the levels of bevacizumab in the milk samples.
Results:
An enzyme-linked immunosorbent assay was developed using antibodies specific to bevacizumab in which the sensitivity threshold was 3 ng/mL. All breast milk samples assayed from the two patients actively undergoing treatment did not have detectable levels of bevacizumab. Samples collected 1.5 hours and 7 hours after an injection and 2 randomly chosen samples were negative by Western blot analysis.
Conclusion:
A sensitive assay to detect bevacizumab in breast milk samples assayed suggests that intravitreal injections do not result in detectable bevacizumab in breast milk.
